LUXZYLA (penicillamine) by ANI Pharmaceuticals is clinical pharmacology penicillamine is a chelating agent recommended for the removal of excess copper in patients with wilson’s disease. Approved for the treatment of wilson’s disease, cystinuria, active rheumatoid arthritis and 1 more indications. First approved in 2019.
Drug data last refreshed 19h ago
CLINICAL PHARMACOLOGY Penicillamine is a chelating agent recommended for the removal of excess copper in patients with Wilson’s disease. From in vitro studies which indicate that one atom of copper combines with two molecules of penicillamine, it would appear that 1 g of penicillamine should be…
Worked on LUXZYLA at ANI Pharmaceuticals? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.